<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00353483</url>
  </required_header>
  <id_info>
    <org_study_id>05-0648 / 201101961</org_study_id>
    <nct_id>NCT00353483</nct_id>
  </id_info>
  <brief_title>Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells</brief_title>
  <official_title>Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Washington University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to compare genetic markers present on tumor cells before
      and after chemotherapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this study, the investigators propose that persistent disseminated tumor cells (DTC)
      present after systemic therapy represent a unique subpopulation of all DTC, are predictors of
      a poor response to systemic therapy and correlate with poor clinical outcome. The
      investigators hypothesize that systemic therapy-resistant DTC can be identified by their
      expression of a unique constellation of tumor marker proteins which may be similar to those
      expressed by breast cancer stem cells. In this research, the investigators' specific aims are
      : 1) to characterize tumor markers expressed by DTC which are present after systemic therapy,
      2) to compare the expression of these markers to that on DTC detected prior to systemic
      therapy, 3) to correlate expression of the defined tumor markers on DTC with clinical outcome
      of breast cancer patients to identify those markers that are predictive of disease
      recurrence, 4) to utilize biomarkers identified in Specific Aims 1 and 2 to isolate purified
      DTC for further molecular analysis.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 14, 2005</start_date>
  <completion_date type="Anticipated">August 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize tumor markers expressed by DTC which are present after systemic therapy</measure>
    <time_frame>Approximately 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the expression of these markers to that on DTC detected prior to systemic therapy</measure>
    <time_frame>Approximately 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate expression of the defined tumor markers on DTC with clinical outcome of breast cancer patients to identify those markers that are predictive of disease recurrence.</measure>
    <time_frame>Approximately 6 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Compare the tumor markers present on DTC before and after chemotherapy with the tumor marker expression of the primary tumor and post-treatment tumor.</measure>
    <time_frame>Approximately 6 years.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>To xenograft tumor cells into mice for further genetic and phenotypic characterization.</measure>
    <time_frame>Approximately 5-11 years.</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Tissue, blood, and bone marrow collection</arm_group_label>
    <description>Undergo neoadjuvant systemic therapy
initial surgery for sentinel lymph node biopsy/portacath placement
definitive cancer surgery (if applicable)
when portacath is removed (1 year, if available)
if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis
Undergo Adjuvant Systemic Therapy
initial surgery for a sentinel lymph node biopsy/portacath placement
when portacath is removed (1 year, if available)
If metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis.
Undergone neoadjuvant systemic therapy
during definitive cancer surgery/portacath removal (if available)
if metastatic disease develops or is present in accessible sites, a sample may be collected at the time of specimen collection for diagnosis
An attempt to collect blood on all patients 1/year for 5 years from the time of enrollment</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Peripheral blood draw</intervention_name>
    <arm_group_label>Tissue, blood, and bone marrow collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Breast tissue collection</intervention_name>
    <arm_group_label>Tissue, blood, and bone marrow collection</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone marrow biopsy</intervention_name>
    <arm_group_label>Tissue, blood, and bone marrow collection</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Breast cancer tissue, peripheral blood, and bone marrow
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients seen in clinic at Washington University School of Medicine.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recently diagnosed with clinical stage II, III, or IV breast cancer

          -  Planning to undergo neoadjuvant or adjuvant systemic therapy; patients who have
             already completed neoadjuvant systemic therapy are also eligible

          -  Must be &gt;= 18 years of age

          -  If female, must not be pregnant

          -  Must be willing and able to sign informed consent document
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rebecca Aft, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Washington University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rebecca Aft, MD, PhD</last_name>
    <phone>314-747-0063</phone>
    <email>aftr@wustl.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tracey Guthrie</last_name>
    <phone>314-747-4404</phone>
    <email>guthriet@wustl.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63119</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rebecca Aft, MD, PhD</last_name>
      <phone>314-747-0063</phone>
      <email>aftr@wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Tracey Guthrie</last_name>
      <phone>314-747-4404</phone>
      <email>guthriet@wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca Aft, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mark Watson, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>William Gillanders, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Timothy Eberlein, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Weilbaecher, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Naughton, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shunqiang Li, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie Margenthaler, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Ma, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Cyr, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Katherine Glover-Collins, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Caron Rigden, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rama Suresh, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gregory Longmore, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ashley Frith, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Foluso Ademuyiwa, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Peter Oppelt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Haeseong Park, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ron Bose, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Leonel Hernandez Aya, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mathew Cherian, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lindsay Peterson, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cara Cipriano, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.siteman.wustl.edu</url>
    <description>Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine</description>
  </link>
  <reference>
    <citation>Diel IJ, Cote RJ. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer. Cancer Treat Rev. 2000 Feb;26(1):53-65. Review.</citation>
    <PMID>10660491</PMID>
  </reference>
  <reference>
    <citation>Braun S, Pantel K, Müller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmüller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000 Feb 24;342(8):525-33. Erratum in: N Engl J Med 2000 Jul 27;343(4):308.</citation>
    <PMID>10684910</PMID>
  </reference>
  <reference>
    <citation>Braun S, Naume B. Circulating and disseminated tumor cells. J Clin Oncol. 2005 Mar 10;23(8):1623-6. Review.</citation>
    <PMID>15755968</PMID>
  </reference>
  <reference>
    <citation>Janni W, Rack B, Schindlbeck C, Strobl B, Rjosk D, Braun S, Sommer H, Pantel K, Gerber B, Friese K. The persistence of isolated tumor cells in bone marrow from patients with breast carcinoma predicts an increased risk for recurrence. Cancer. 2005 Mar 1;103(5):884-91.</citation>
    <PMID>15666325</PMID>
  </reference>
  <reference>
    <citation>Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmüller G. Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet. 2002 Aug 31;360(9334):683-9.</citation>
    <PMID>12241875</PMID>
  </reference>
  <reference>
    <citation>Choesmel V, Pierga JY, Nos C, Vincent-Salomon A, Sigal-Zafrani B, Thiery JP, Blin N. Enrichment methods to detect bone marrow micrometastases in breast carcinoma patients: clinical relevance. Breast Cancer Res. 2004;6(5):R556-70. Epub 2004 Jul 29.</citation>
    <PMID>15318937</PMID>
  </reference>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 17, 2006</study_first_submitted>
  <study_first_submitted_qc>July 17, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2006</study_first_posted>
  <last_update_submitted>April 12, 2018</last_update_submitted>
  <last_update_submitted_qc>April 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Neoadjuvant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

